Abstract. This study determined the serum procalcitonin (PCT) levels in patients with myocardial infarction complicated by pulmonary infection and explore its clinical significance and diagnostic value. A total of 473 patients who were admitted to the Third Affiliated Hospital of Qiqihar Medical University from January 2016 to June 2017 were enrolled as research subjects. Patients were divided into four groups based on their symptom status in myocardial infarction and pulmonary infection. There were 109 patients in normal control group who did not experience symptoms of either myocardial infarction or pulmonary infection. Blood samples were collected from each patient, and PCT levels were measured. The data were analyzed. The serum PCT levels prior to treatment were compared with each other. The PCT levels in the myocardial infarction and the pulmonary infection group were all higher than that in the normal control group (0.040±0.015) (p<0.05). On the contrary, the serum PCT level in the myocardial infarction complicated by pulmonary infection group was higher than that in the normal control group (p<0.001). The serum PCT level after treatment was compared with that before treatment within the same group. The serum PCT levels in the three disease groups were comparable after treatment. The differences in PCT levels before and after treatment were all statistically significant within all three groups (p<0.05). A patient's serum PCT level was correlated with myocardial infarction complicated by pulmonary infection, which suggested it can be used as an important diagnostic marker for this complication. This finding has important clinical value for predicting and evaluating the complicated condition of myocardial infarction and pulmonary infection by providing a more accurate, sensitive, and specific method for early diagnosis of the disease.
Introduction
Acute myocardial infarction (AMI) is one of the acute and critical cardiovascular diseases that are commonly seen in clinic. The patient often suffers from severe pain beneath the sternum, and the pain cannot be relieved with rest. Other symptoms include alteration of serum myocardial enzyme levels, abnormal electrocardiogram, abnormal hematological parameters, and increased body temperature (1, 2) . AMI is an extremely dangerous condition with high mortality and disability rates. It seriously threatens patient's life and inflicts great pain to patients and their families (3) . Clinically, myocardial infarction is often complicated by pulmonary infection. Myocardial infarction complicated by pulmonary infection poses a higher risk of death to patients and is more difficult to treat (4) . Pulmonary infection is a common condition in clinic, which can be resulted from chemical, physical and allergic factors, and pathogenic microorganisms (5) . Pulmonary infection requires timely and effective antibiotic intervention and other treatment measures. In recent years, basic medical research on this topic has continuously improved. A research report stated that serum levels of inflammatory factors were significantly elevated in patients with myocardial infarction complicated by pulmonary infection, which in turn promotes atherosclerosis, thereby creating a vicious circle. The complication increases difficulties in clinical treatments, and inflicts further harm to patients' health and life (6) .
At present, the commonly used diagnostic indicators for evaluating inflammatory response in myocardial infarction include erythrocyte sedimentation rate (ESR), white blood cell (WBC) count, and high-sensitivity C-reactive protein (hs-CRP) (7) (8) (9) . However, these diagnostic indicators have disadvantages and limitations such as strict requirement in sample collecting time, low sensitivity, poor specificity, easy contamination, antibiotic interference, high cost, and long waiting time, suggesting that they are not appropriate to be used for diagnosis of myocardial infarction complicated by pulmonary infection (10) (11) (12) . Through comparative analysis, procalcitonin (PCT) was deemed to be not plagued by these disadvantageous factors. PCT is a sensitive and specific indicator of inflammation. So far it has not been reported in literature that serum PCT was ever used as a clinical diagnostic indicator of myocardial infarction complicated by pulmonary infection. In this study, the serum PCT level in patients with myocardial infarction complicated by pulmonary infection was determined, and its clinical significance and diagnostic value were explored.
Materials and methods

Materials.
A total of 473 patients who were admitted to the Clinical Laboratory, the Third Affiliated Hospital of Qiqihar Medical University (Qiqihar, China) from January 2016 to June 2017 were enrolled as research subjects. Patients were divided into four groups based on their symptom status in myocardial infarction and pulmonary infection. There were 109 patients in normal control group who did not have either myocardial infarction or pulmonary infection; 118 patients in myocardial infarction group; 121 patients in pulmonary infection group; and 125 patients in myocardial infarction complicated by pulmonary infection group. The general clinical data such as age and sex were comparable, and there were no statistically significant differences between the four groups. Diagnosis of myocardial infarction was based on the 2012 ACC Guideline for the Management of ST-Elevation Myocardial Infarction. All subjects were inquired about their medical history, and underwent multiple examinations including physical, electrocardiography, ultrasonography, and coronary angiography. The diagnostic criteria for AMI recommended by the World Health Organization (WHO) were followed in the diagnosis. Specifically, the presence of two of the three indicators, i.e., chest pain, abnormal electrocardiogram and abnormal myocardial enzyme levels, was required to confirm the diagnosis of AMI. The diagnosis of pulmonary infection was based on the guidelines published by the Chinese Society of Respiratory Diseases in 2013. Basically, patients were diagnosed to have pulmonary infection by both pulmonary CT and sputum culture, and patients did not have a history of pulmonary infection in the past 1 year. Patients were diagnosed to have myocardial infarction complicated by pulmonary infection if all the diagnostic criteria mentioned above for both myocardial infarction and pulmonary infection were met at the same time.
Patients were excluded from the study if the following conditions were present: Cardiogenic shock, intoxication, peripheral vascular diseases, stroke, disturbance of consciousness, renal dysfunction, severe infection, sepsis, malignant tumors, acute pancreatitis, stable angina, thyroid diseases, autoimmune diseases, metabolic diseases, severe organ perfusion abnormalities, serious injury, severe liver dysfunction, severe burns, medullary thyroid C cell carcinoma, blood system diseases, cerebrovascular accident, and other diseases affecting PCT and inflammatory factors. Those patients who received anti-inflammatory drug treatment before admission were also excluded. This study was approved by the Medical Ethics Committee of the Third Affiliated Hospital of Qiqihar Medical University. All patients participating in this study or their families signed informed consent and volunteered to participate in this study.
Methods. Venous blood samples (5 ml) were taken from all patients under fasting at following time-points: In the morning following admission; after pulmonary infection was diagnosed (at 48 h after admission for patients without pulmonary infection) and at discharge. The blood samples were centrifuged at 500 x g for 10 min at 4˚C using a centrifuge manufactured by Anhui Zhongke Zhongjia Scientific Instrument Co., Ltd. (Hefei, China). The supernatant (serum) was collected and used for the following PCT analysis. The serum PCT level was determined using a PCT quantification kit in conjunction with the electrochemiluminescence immunoassay. The kit was used strictly in accordance with the manufacturer's protocol. The immunoassay was performed on an up-converting phosphor technology (UPT)-based immunoassay analyzer manufactured by Beijing Hotgen Biotechnology Co., Ltd. (Beijing, China). Up-converting phosphor (UCP) particles are used in the UPT immunoassay as the bio-label, which emit visible light in the wavelength range of 475-670 nm under excitation of infrared light with a wavelength >780 nm. The UPT immunoassay can allow for accurate determination of serum PCT levels. A PCT level >0.5 ng/ml was used as a positive reference value.
Statistical analysis. The SPSS 21.0 (IBM Corp., Armonk, NY, USA) statistics software was used for statistical analysis. Measurement data that were normally distributed were expressed as mean ± standard deviation. Measurement data that were not normally distributed were presented as median and interquartile range. The rank-sum test was used in measurement data comparison between groups. Qualitative data were expressed as a percentage (%). The χ 2 test was used in qualitative data comparison between groups. The significance level α was set as 0.05.
Results
General data of patients in each group. As shown in Table I , the age and sex among patients in the four groups were comparable. There were no statistically significant differences between the groups (p>0.05).
Serum PCT levels before treatment. Before treatment, the serum PCT levels in the normal control, myocardial infarction, pulmonary infection, and myocardial infarction complicated by pulmonary infection group were 0.040±0.015, 0.080±0.022, 0.170±0.050 and 0.580±0.075 ng/ml, respectively (Table Ⅱ) . Compared with the normal control group, the PCT levels in other three groups were all higher, and the differences were statistically significant (p<0.05). It is worth pointing out that the PCT level in the myocardial infarction complicated by pulmonary infection group was higher than the positive reference value (0.5 ng/ml).
Comparison of serum PCT levels before and after treatment in four groups. The serum PCT levels in the four groups were comparable after treatment (Table Ⅲ) . Although the differences in PCT levels before and after treatment were all statistically significant within the three disease groups, the decrease in the myocardial infarction complicated by pulmonary infection group (p<0.001) was substantially larger than those in the myocardial infarction and the pulmonary infection group (p<0.05).
Discussion
AMI refers to myocardial necrosis caused by acute, severe and persistent ischemia or hypoxia when a coronary artery becomes occluded. Risk factors for a coronary artery occlusion include unhealthy lifestyles such as overeating, overwork, agitation, constipation and smoking (13) . Myocardial ischemic necrosis is due to thrombotic occlusion of coronary arteries resulting from inflammatory mechanisms, or plaque rupture (14) . Myocardial infarction has high morbidity and mortality with 5-year mortality being higher than that of malignant tumors. As a critical cardiovascular disease commonly seen in clinic, clinicians have always been paying a particular attention to AMI. In addition, research on AMI has become the focus of current research in cardiology. Although association of hs-CRP with AMI has been extensively studied, it does not reflect the inflammatory response induced by AMI due to its low specificity. In recent years, PCT has drawn much attention and gradually become a preferred indicator of inflammatory response induced by AMI. It has gained wide applications in the cardiovascular field (15) .
PCT is an inactive precursor of calcitonin. First of all, preprocalcitonin (prePCT) is synthesized in the rough endoplasmic reticulum of thyroid parafollicular cells under normal physiological conditions. The prePCT then enters the endoplasmic reticulum membrane of other cells and undergoes glycosylation and specific enzymatic excision of N-terminal signal peptide producing PCT (16) . In recent years, significant increase in PCT level has been observed mainly in severe inflammatory reactions, multiple organ failure, and endotoxemia in the clinic. In other cases, such as mild infection, viral infection and autoimmune reaction, the PCT level generally remained the same or only slightly increased. According to literature, PCT is extensively used as a disease indicator in cardiovascular-related fields (17) . Clinically, AMI results from a coronary artery occlusion leading to myocardial ischemic necrosis. This condition induces a sterile inflammatory response, in which PCT is an important indicator of the intensity (18) . The serum PCT level and vascular endothelial growth factor-B (VEGF-B) expression level in elderly patients with AMI were reported to have certain relevance with the patients' prognosis. Related studies have demonstrated that quantitative PCT measurement has important guiding significance for diagnosis, assessment and prognosis of patients with myocardial infarction (19) .
Infection is implicated in AMI. Hematological abnormality, increased body temperature and other inflammatory manifestations often occur in patients with AMI. The patients are prone to combined lung infection, which in turn is one of the leading causes of aggravating myocardial infarction. Early diagnosis of myocardial infarction complicated by pulmonary infection is a pressing issue that needs to be solved in clinical treatment and control of the condition (20) . Those commonly used markers in the clinic, such as ESR and C-reactive protein are effective but not specific in diagnosis of myocardial infarction complicated by pulmonary infection. Lack of specific markers for accurate and rapid diagnosis and prediction of the complication prompted us to explore in this study if serum PCT can be used as a specific marker in diagnosis of the disease. The serum PCT level prior to treatment was compared with each group. The PCT levels (ng/ml) in the myocardial infarction group (0.080±0.022) and in the pulmonary infection group (0.170±0.050) were all higher than that in the normal control group (0.040±0.015). Although the differences were statistically significant (p<0.05), these levels were all in the lower range (<0.5 ng/ml). On the contrary, the serum PCT level in the myocardial infarction complicated by pulmonary infection group (0.580±0.075) was in a higher range (>0.5 ng/ml), and was substantially higher than that in the normal control group (p<0.001). The serum PCT level after treatment was compared with that before treatment within the same group. The serum PCT levels in the three disease groups were comparable after treatment, i.e., 0.042±0.020 in the myocardial infarction group, 0.041±0.021 in the pulmonary infection group, and 0.049±0.022 in the myocardial infarction complicated by pulmonary infection group. Although the differences in PCT levels before and after treatment were all statistically significant within all three groups, the decrease in the myocardial infarction complicated by pulmonary infection group (p<0.001) was larger than those in the myocardial infarction group and the pulmonary infection group (p<0.05). These findings demonstrated that the serum PCT can be used as a specific diagnostic indicator of myocardial infarction complicated by pulmonary infection due to substantial increase in its level when the complication occurs.
When pulmonary infection occurs in patients with myocardial infarction, early and timely intervention of the infection has important clinical implications for improving the condition of myocardial infarction. Some patients may not show characteristic symptoms of pulmonary infection such as fever, abnormal results of complete blood count and chest X-ray in an early stage. Delayed diagnosis and treatment of patients with occult pulmonary infection may impact the treatment and recovery of myocardial infarction negatively. Therefore, rapid and accurate diagnosis of myocardial infarction complicated by pulmonary infection is crucial to patients' overall treatment and prognosis. In this study, it was found that the serum PCT level in patients with myocardial infarction complicated by pulmonary infection was significantly higher than that in patients with myocardial infarction only. Clinically, quantification of serum PCT in patients can help diagnose myocardial infarction complicated by pulmonary infection, which may play an important role in accurate diagnosis and timely treatment of the complication. In the present study, using a large number of subjects a validated threshold value of the serum PCT level in patients with myocardial infarction complicated by pulmonary infection was 0.5 ng/ml, which was consistent with the literature (21) . It was reported that the sensitivity of a serum PCT level >0.5 ng/ml was ~97% for the diagnosis of chronic cardiac insufficiency complicated by pulmonary infection (22, 23) . The sensitivity and specificity of a threshold value of 2 ng/ml were 89 and 94%, respectively (24, 25) . In the current study, the serum PCT level in patients with myocardial infarction complicated by pulmonary infection was 0.580 ng/ml. This value had a sensitivity of 92.7%, a specificity of 93% and a negative predictive value of 74.5%. Both the sensitivity and the specificity were in a good range. Patients with myocardial infarction tend to have pulmonary infection, which in turn can worsen the condition of myocardial infarction. The serum PCT, as a new marker, has high specificity and high sensitivity when applied in the clinic, providing a strong support for diagnosis of myocardial infarction complicated by pulmonary infection.
In conclusion, the serum PCT level in patients with myocardial infarction complicated by pulmonary infection increased substantially above the positive reference value of 0.5 ng/ml, and was significantly higher than that in the normal control, the myocardial infarction and the pulmonary infection group. After treatment, the serum PCT level in patients with myocardial infarction complicated by pulmonary infection decreased significantly to a level comparable to that in other groups. Serum PCT assay had a very high sensitivity and specificity for the diagnosis of myocardial infarction complicated by pulmonary infection. It helps in clinical diagnosis and prediction of myocardial infarction complicated by pulmonary infection, and allows patients to receive appropriate and effective treatment in the early stage.
